<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6310">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03024788</url>
  </required_header>
  <id_info>
    <org_study_id>2016YFC1305700d</org_study_id>
    <nct_id>NCT03024788</nct_id>
  </id_info>
  <brief_title>Determination of Cut-off Value of AGEsP and HbA1c in Type 2 Diabetes Diagnosis in China</brief_title>
  <official_title>Determination of Cut-off Value of Advanced Glycation End-product and Glycosylated Haemoglobin in Type 2 Diabetes Diagnosis in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhongda Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhongda Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study of the correlation between AGEsP and HbA1c and diabetic retinopathy prevalence:
      determination of cut-off value of AGEsP and HbA1c in type 2 diabetes diagnosis in China
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To find the cut-off point of AGEsP and HbA1c for diagnosis of diabetes by drawing the
      logistic regression model between prevalence of retinopathy and AGEsP level and HbA1c
      level,and find the point where the prevalence of retinopathy changes most rapidly.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date>December 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>prevalence of retinopathy</measure>
    <time_frame>3 years</time_frame>
    <description>the prevalence of retinopathy in different AGEsP and HbA1c levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of retinopathy</measure>
    <time_frame>3 years</time_frame>
    <description>incidence of retinopathy in different AGEsP and HbA1c levels</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">6000</enrollment>
  <condition>Type II Diabetes</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>syringe, fundus camera etc</intervention_name>
    <description>Physical examination, fundus examination, blood and urine samples collection</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Chinese natural population
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  20~70 years old;

          -  Volunteer to participate in this study and signed informed consent.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 19, 2017</lastchanged_date>
  <firstreceived_date>January 11, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhongda Hospital</investigator_affiliation>
    <investigator_full_name>Zilin Sun</investigator_full_name>
    <investigator_title>director physician</investigator_title>
  </responsible_party>
  <keyword>Glycosylated haemoglobin</keyword>
  <keyword>advanced glycation end products</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
